Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG-PPD hypersensitivity and safety in healthy subjects and tuberculosis patients
CTR20222278Phase 2Completed
- Sponsor
- Chengdu Keen Biotechnology
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tuberculin purified protein derivative in Tuberculosis (TB), sponsored by Chengdu Keen Biotechnology. Started Sep 2022; status: completed.
02
Drugs
tuberculin purified protein derivative
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on CTR20222278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222278.